Article Text

Download PDFPDF
Golimumab for ulcerative colitis: adding perspective to the pursuit
  1. Jimmy K Limdi1,2
  1. 1 Section of IBD, Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, UK
  2. 2 Manchester Academic Health Sciences, University of Manchester Institute of Inflammation and Repair, Manchester, UK
  1. Correspondence to Dr Jimmy K Limdi, Section of IBD, Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester M13 9PL, UK; Jimmy.Limdi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Anti-TNF therapies have had a transformational effect on our treatment paradigms for ulcerative colitis (UC). Golimumab (GLM) received regulatory approval for the treatment of moderately to severely active UC, following demonstration of efficacy and safety in the induction (PURSUIT-SC) and maintenance (PURSUIT-M) trials.1 2 The trial objective was to obtain regulatory approval, not to inform clinicians on optimising its use in clinical practice. In that sense, the inclusion of anti-TNF naive patients arguably represented ‘low-hanging fruit’. Yet, trials leave a trail that subsequent studies must tread.

Adding to our understanding, Samaan and colleagues present a timely ‘real-world’ experience with GLM from two tertiary inflammatory bowel disease (IBD) centres. …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Colorectal
    Mark A Samaan Polychronis Pavlidis Jonathan Digby-Bell Emma L Johnston Angad Dhillon Ramesh Paramsothy Abisoye O Akintimehin Lucy Medcalf Guy Chung-Faye Patrick DuBois Ioannis Koumoutsos Nick Powell Simon H C Anderson Jeremy Sanderson Bu’ Hussain Hayee Peter M Irving